- Precipitate formation: visible white or crystalline particles (e.g., calcium + phosphate, phenytoin + dextrose)
- Turbidity: solution becomes cloudy or hazy, particles too small to see
- Color change: yellow, brown, or dark discoloration indicating degradation
- Gas formation: bubbling due to chemical reaction between agents
- Any visible change = DO NOT administer — discard and start fresh
- Hydrolysis: water breaks drug molecules (e.g., ampicillin degrades rapidly in dextrose)
- Oxidation: exposure to light, oxygen reduces drug potency (e.g., nitroglycerin, furosemide)
- Reduction: drug loses electrons, altering structure and efficacy
- Complexation: binding between agents forms inactive complexes
- May be invisible — silent loss of drug efficacy with no physical signs
- Most drugs have optimal stability within narrow pH ranges
- Acidic drugs (pH 2–5): furosemide, aciclovir, dopamine
- Alkaline drugs (pH 8–11): phenytoin, thiopental, ampicillin
- Mixing acid + alkaline drugs → precipitate or degradation
- Blood (pH 7.35–7.45) can precipitate alkaline drugs at IV site
- Always check individual drug pH before Y-site administration
- Certain lipophilic drugs bind to PVC (polyvinyl chloride) tubing walls
- Nitroglycerin: up to 80% lost to PVC — use non-PVC/polyethylene tubing
- Insulin: adsorbs to glass and PVC — flush tubing before use; accounts for 10–50% loss
- Diazepam, amiodarone, cyclosporine: significant PVC adsorption
- Use polyurethane or polyolefin tubing when mandated by drug monograph
- Normal plasma osmolality: 285–295 mOsm/kg
- Peripheral IV max recommended: 600–900 mOsm/L
- Hypertonic solutions via peripheral line → chemical phlebitis, vein damage
- KCl, MgSO4, mannitol 20%, TPN: require central venous access
- NaCl 23.4%: must ONLY be given via central line — fatal if given peripherally
- Dextrose >10% requires central access in most GCC protocols
- Y-site: two drugs infused simultaneously at a Y-connector — contact is brief but real
- Admixture: drugs mixed in same bag/syringe — prolonged contact, higher incompatibility risk
- Sequential: one drug infused after another with flush between — safest approach for uncertain pairs
- Y-site compatibility ≠ admixture compatibility — always check the correct route
- Flush with 10 mL NaCl 0.9% between sequential infusions to prevent interaction
⚡ Interactive IV Compatibility Checker
Select two drugs to check their Y-site or line compatibility. Based on Trissel's data and ASHP guidelines.
| Drug Pair | Status | Mechanism | Clinical Risk | Safe Alternative |
|---|---|---|---|---|
| Furosemide + Aminophylline | Incompatible | Precipitate formation (furosemide alkaline pH + aminophylline) | Particulate embolism, loss of efficacy | Separate lines or sequential with flush |
| Phenytoin + Dextrose (5%/10%) | Incompatible | Crystallization; phenytoin precipitates in glucose solutions | Microvascular occlusion, catheter blockage | Use NaCl 0.9% only for phenytoin diluent |
| Amphotericin B + Normal Saline | Incompatible | Ionic interaction causes aggregation of colloidal particles | Loss of drug, infusion reaction | Dilute in D5W only; never use NaCl |
| Aciclovir + Most Drugs | Caution | Highly alkaline pH (9–11) causes precipitation with many drugs | Precipitate formation, phlebitis | Dedicated line; flush before/after; dilute to ≤7 mg/mL |
| Co-trimoxazole + Fluconazole | Incompatible | Precipitate forms at Y-site | Particulate infusion, blocked line | Sequential administration with flush |
| Calcium Gluconate + Phosphate | Incompatible | Calcium phosphate salt precipitate (especially in TPN) | Fatal pulmonary embolism (documented deaths) | Use separate lumens; pharmacy to calculate TPN Ca:P ratio |
| Calcium + Sodium Bicarbonate | Incompatible | Calcium carbonate precipitate forms immediately | Gross precipitation, line occlusion | Never co-infuse; flush vigorously between doses |
| Vancomycin + Heparin | Incompatible | Vancomycin (low pH) + heparin (alkaline) precipitates | Precipitate, subtherapeutic vancomycin levels | Separate IV access; flush with 10 mL NaCl between |
| Vancomycin + Piperacillin-Tazobactam | Caution | Possible nephrotoxicity synergy (pharmacodynamic) | Acute kidney injury risk elevated | Monitor renal function closely; consider alternative beta-lactam |
| Insulin + PVC Tubing | Caution | Adsorption to PVC and glass; 10–50% dose lost | Unpredictable glycaemic control | Flush tubing with 50 mL insulin solution before use; recheck BGL |
| Propofol + Incompatible Diluents | Caution | Lipid emulsion disrupted by electrolytes, pH changes | Emulsion breakdown, fat emboli risk | Do not mix with anything; use dedicated line; discard after 12 h |
| Nitroglycerin + PVC | Incompatible | Adsorption — up to 80% lost in standard PVC tubing | Subtherapeutic dosing in angina/hypertension | Use non-PVC polyethylene or glass infusion sets |
| Amiodarone + Heparin | Incompatible | Precipitate at Y-site; amiodarone also adsorbs to PVC | Particulate infusion, subtherapeutic levels | Dedicated lumen; non-PVC tubing for amiodarone |
| Midazolam + Sodium Bicarbonate | Incompatible | Precipitate at alkaline pH | Gross precipitation, line block | Separate infusions; never mix in same line |
| Dopamine + Sodium Bicarbonate | Incompatible | Alkaline environment inactivates catecholamine | Loss of vasopressor effect — haemodynamic collapse risk | Never co-infuse; dedicated vasopressor lumen |
| Morphine + Furosemide | Compatible | Stable at Y-site in standard concentrations | None documented at therapeutic doses | Y-site acceptable; monitor closely |
| Heparin + Insulin | Caution | Complex formation may reduce both drug activities | Unpredictable anticoagulation; glycaemic variability | Separate dedicated lines preferred in ICU |
CONCENTRATED ELECTROLYTES
KCl >10 mEq/50mL, NaCl 23.4%, MgSO4 50%, sodium phosphate. Never store concentrated KCl on wards — fatal IV bolus cases documented. Must be diluted and infused via pump only. Tall man lettering: potassium CHLORIDE.
INSULIN (All Types)
10-fold dosing errors common (units vs mL confusion). Only use insulin syringes. Never abbreviate "U" as it is mistaken for "0". Adsorbs to PVC — flush tubing. Subcutaneous vs IV routes must never be confused.
UNFRACTIONATED HEPARIN
Weight-based dosing requires pharmacy protocol. Heparin 1,000 units/mL vs 10 units/mL vials look identical in some countries. Double-check vial concentration. aPTT monitoring mandatory. Protamine available as reversal agent.
NEUROMUSCULAR BLOCKING AGENTS
Vecuronium, rocuronium, atracurium, succinylcholine. Patient will be PARALYSED — must be intubated and ventilated. Never store on open ward shelves. Requires anaesthesia/ICU-level monitoring. Fatal if given without ventilator support.
CONCENTRATED OPIOIDS
Morphine 10 mg/mL, fentanyl 50 mcg/mL, hydromorphone. Respiratory depression risk. Naloxone must be at bedside. 10-fold errors: 1 mg/mL vs 10 mg/mL morphine look similar. Use weight-based dosing and smart pumps with dose error reduction software (DERS).
CHEMOTHERAPY AGENTS
Methotrexate, vincristine, cyclophosphamide, cisplatin. Intrathecal vs IV vincristine mix-ups have been fatal (WHO alert). Requires two-nurse verification, pharmacy preparation only, cytotoxic PPE. Strict extravasation protocols (vesicants).
HYPERTONIC DEXTROSE (>10%)
D50W used for hypoglycaemia treatment — severe extravasation if peripherally placed. Central line preferred. Osmotic injury to veins. Always dilute to appropriate concentration. Rebound hyperglycaemia risk.
THROMBOLYTICS (tPA, Streptokinase)
Alteplase, tenecteplase, streptokinase. Systemic bleeding risk. Contraindications must be checked before administration. Time-sensitive (door-to-needle). No other IV medications to run concurrently during infusion period without pharmacy approval.
Independent Double-Check
Two nurses verify drug name, dose, concentration, route, rate, and patient ID independently — before preparing AND before administering.
Tall Man Lettering
Use standardized tall man lettering in all documentation: vinCRIStine vs vinBLAStine, hydrALAZINE vs hydrOXYzine, DOBUTamine vs DOPamine.
Smart Pump Programming
Programme all high-alert infusions into smart pump with DERS (Dose Error Reduction Software). Use hospital drug library. Override requires supervisor approval and documentation.
Dedicated IV Lines
High-alert medications — especially vasopressors, insulin infusions, and neuromuscular blockers — must run through dedicated lumens. No shared Y-site without pharmacist verification.
10-Fold Error Prevention
When ordered dose differs from standard concentration by a factor of 10, re-verify with prescriber. Most fatal medication errors involve a 10-fold miscalculation. Calculate mg/kg/min independently.
- Concentrated KCl: pharmacy only — never on general wards
- NMBAs: locked cabinet, ICU/OT only
- Concentrated opioids: controlled drug cabinet
- Thrombolytics: refrigerated, pharmacy-controlled
- Auxiliary warning labels: "HIGH ALERT MEDICATION"
- Red stickers on all high-alert IV bags in GCC hospitals
- Label must show: drug, dose, concentration, rate, expiry, preparer
- Chemotherapy: cytotoxic purple labels (ASHP standard)
- Naloxone → opioid reversal (0.4 mg IV, repeat every 2–3 min)
- Protamine → heparin reversal (1 mg per 100 units heparin)
- Sugammadex → rocuronium/vecuronium reversal
- Glucagon → beta-blocker/calcium channel blocker overdose
- Indications: TPN, hypertonic solutions, vasopressors, long-term antibiotics, chemotherapy, CVVH
- CVC tip position: lower third SVC / cavoatrial junction — confirm by CXR before use
- PICC: basilic or brachial vein insertion, tip at SVC; suitable for weeks to months
- Port (implanted): accessed with Huber needle only; never use standard needle
- Multi-lumen CVCs: assign each lumen a dedicated purpose; label at connection point
- Site selection priority: forearm → antecubital → hand → wrist (avoid wrist — risk of radial nerve damage)
- Never use: lower limb veins, phlebitic sites, site on same side as mastectomy/lymphoedema
- Maximum osmolality via peripheral: 600–900 mOsm/L
- Rotation: every 72–96 hours (GCC standard per JCI/DHA guidelines)
- Gauge selection: 22G routine, 18G blood transfusion, 14–16G trauma resuscitation
The push-pause (pulsatile) technique creates turbulent flow that removes fibrin and drug residue from catheter walls more effectively than continuous slow flushing.
Assess patency
Aspirate for blood return before each infusion — confirms catheter position. Absence of flashback in PICC/CVC = investigate before using.
Pre-infusion flush
Flush with 10 mL NaCl 0.9% using push-pause technique (1 mL push, brief pause, 1 mL push) to clear lumen and confirm patency.
Administer medication
Connect infusion, set rate per prescription. Monitor patient and IV site for first 5–10 minutes of new infusion.
Post-infusion flush
Flush with 10 mL NaCl 0.9% push-pause immediately after each drug to clear dead space and prevent incompatibility with next agent.
Lock solution
Apply lock per local protocol: heparinised saline (10 units/mL) for multi-lumen CVCs and PICCs; saline-only for peripheral cannulas. Positive pressure technique on disconnect.
- Peripheral IV: Saline lock (10 mL NaCl) — no heparin needed for short dwell
- PICC / open-ended CVC: Heparinised saline 10 units/mL — 5 mL per lumen
- Closed-ended valved catheter (Groshong): Saline-only lock (heparin not needed)
- Clamping sequence (heparin last — SASH): Saline → Administration → Saline → Heparin
- Always maintain positive pressure on syringe while disconnecting to prevent backflow
- Alcohol cap/needleless connector: scrub hub 15 seconds with 70% alcohol, allow 5 sec dry time
- 0.2 μm (air-eliminating + particulate): TPN (fat-free), blood product pre-filters, most IV drugs — removes bacteria, particulates, air
- 1.2 μm filter: TPN with lipid emulsions (3-in-1 admixtures) — 0.2 μm clogs with lipid particles
- Blood administration set (170–260 μm): All blood products; change after each unit or every 4 hours
- Do NOT use 0.2 μm filter with: lipid emulsions, blood products, liposomal drugs (amphotericin B liposomal)
- Change filters per manufacturer guidance (usually every 24–72 h) or when occluded
Red label "ARTERIAL — DO NOT INJECT". Trace line from patient before any administration. Accidental drug injection into arterial line = limb-threatening emergency.
Label must include: drug name + dose, diluent + volume, rate, start/expiry date-time, prepared by + checked by, patient ID, batch number (JCI standard).
Yellow label "EPIDURAL ONLY — NOT FOR IV USE". Different connectors required (ISO 80369-6). Never use standard Luer-lock for neuraxial infusions.
No signs of phlebitis
IV site healthy. Continue to observe.
Possible first signs of phlebitis
Slight pain OR redness near IV site. Observe cannula.
Early stage of phlebitis
Two of: pain, erythema, swelling. Re-site cannula.
Medium stage of phlebitis
All of: pain, erythema, induration. Re-site cannula and consider treatment.
Advanced stage or start of thrombophlebitis
Pain, erythema, induration, palpable venous cord (>1 inch). Re-site; consider treatment and document.
Advanced stage of thrombophlebitis
Pain, erythema, induration, palpable cord >1 inch, pyrexia. Initiate treatment; escalate to medical team; IV therapy review required.
Extravasation causes progressive tissue necrosis, potentially requiring surgical debridement or skin grafting. Extreme caution required; central line preferred where feasible.
Extravasation causes pain, inflammation and thrombophlebitis but generally does not cause full-thickness necrosis. Still requires prompt management and site change.
STOP the infusion immediately
Do not remove the cannula yet. Leave it in place for aspiration.
Aspirate through the cannula
Attempt to withdraw 3–5 mL of drug/fluid from the site before removing the cannula. Do NOT flush the site.
Remove the cannula
Once aspiration attempted, remove IV cannula. Do not apply pressure that could further spread the drug.
Mark and photograph the area
Mark the perimeter of extravasation with a skin marker. Photograph for documentation and monitoring progression.
Apply antidote / compress per drug type
See antidote guide below. Elevate limb above heart level to reduce oedema.
Notify medical team and document
Complete incident report. Refer to plastic surgery if tissue necrosis, blistering, or area >2 cm develops within 24–48 hours.
| Drug / Class | Antidote | Compress | Notes |
|---|---|---|---|
| Anthracyclines (Doxorubicin, Daunorubicin) | Dexrazoxane IV (Savene) within 6 h; OR DMSO 99% topically q6h × 7 days | Cold compress 15–20 min × 4/day for 1–2 days | Do NOT use warm; avoid occlusive dressings with DMSO |
| Vinca Alkaloids (Vincristine, Vinblastine) | Hyaluronidase 150–1500 units SC into site (multiple injections around perimeter) | Warm compress 15–20 min × 4/day | Warm compress promotes hyaluronidase dispersion; start within 1 hour |
| Hyperosmolar solutions (Dextrose >10%, KCl, TPN, NaCl 23.4%) | Hyaluronidase 150 units SC around perimeter | Warm compress to promote absorption | Elevate limb; monitor for necrosis at 24–48 h |
| Vasopressors (Noradrenaline, Dopamine high-dose) | Phentolamine 5–10 mg in 10 mL NaCl, inject locally within 12 h | Warm compress after phentolamine | Blanching/cyanosis indicates ischaemia — urgent treatment needed |
| Calcium chloride / gluconate | Hyaluronidase; sodium thiosulphate for calcium chloride | Warm compress | Calcium chloride (10%) is far more caustic than gluconate |
| General irritants (Vancomycin, Aciclovir) | No specific antidote — supportive care | Cold compress for pain relief | Elevate, document, re-site; topical corticosteroid cream for inflammation |
- Peripheral cannulas: change every 72–96 hours (JCI / GCC standard)
- Change immediately if any sign of phlebitis (VIP ≥ 2)
- Document insertion date on dressing and IV chart
- Consider clinically indicated replacement for long-dwell PIVs
- Use smallest gauge cannula appropriate for therapy
- Secure adequately — movement causes mechanical phlebitis
- Aseptic non-touch technique (ANTT) for all insertions
- Chlorhexidine 2% / alcohol 70% skin prep; dry before insertion
- Dilute irritant drugs adequately before infusion
- Infuse over recommended time — too fast increases phlebitis risk
- Check osmolality of admixtures for peripheral use
- In-line filter use reduces phlebitis from particulates
| Country / Authority | Regulatory Body | Key Formulary Notes |
|---|---|---|
| Dubai, UAE | DHA (Dubai Health Authority) | DHA Formulary Tier system. High-alert medications require mandatory pharmacy counselling. Non-formulary requests need CMO/senior pharmacist approval. Smart pump DERS mandatory in DHA hospitals since 2021. |
| Abu Dhabi, UAE | DOH (Department of Health) | DOH Formulary with HAAD-derived standards. IV medication preparation must follow USP 797 standards in DOH-licensed facilities. Sterile compounding SOPs strictly regulated. |
| Other Emirates, UAE | MOH UAE | MOH National Formulary. Some medications available in DHA/DOH not on MOH formulary. Nurses must be aware of regional differences when transferring patients. |
| Saudi Arabia | SFDA / SCFHS | Saudi National Formulary. SFDA regulates drug availability. SCFHS (Saudi Commission for Health Specialties) governs nursing practice standards. Vision 2030 driving digitisation of IV medication records. |
| Qatar | QCHP (Qatar Council for Healthcare Practitioners) | QCHP Formulary aligned with NHS and international standards. Hamad Medical Corporation (HMC) has its own IV drug monograph system available to all nurses electronically. |
| Oman | OMSB (Oman Medical Specialty Board) | MOH Oman Formulary. OMSB provides clinical practice guidelines. IV drug preparation protocols follow WHO guidelines with local adaptations. |
| Bahrain | NHRA (National Health Regulatory Authority) | NHRA Drug Formulary. Smaller formulary than UAE/KSA. Nurses may encounter off-formulary requests requiring NHRA exemption approval. |
| Kuwait | MOH Kuwait | Kuwait National Drug Formulary. Drug availability can vary between MOH, KFSH, and military hospitals. IV drug preparation generally centralised in pharmacy. |
- Medications containing glucose additives may be considered to break fast — check with patient
- TPN and high-calorie IV solutions are generally considered to invalidate fasting by most scholars
- Nurses should document patient's fasting status in medication administration record
- Timing adjustments: Where clinically safe, consider shifting non-urgent IV doses to night window (between Iftar and Suhoor) in liaison with medical team
- Dehydration risk: Higher during Ramadan — vigilant IV site assessment; vein quality may be reduced
- Electrolyte management: Ramadan affects fluid and electrolyte balance — more frequent IV electrolyte checks may be needed
- Insulin infusions: Basal insulin requirements change significantly during Ramadan — coordinate with endocrinology
- Cultural sensitivity: Always offer private space for patient prayers; minimise interruptions during prayer times; schedule IV assessments around prayer schedule where possible
Temperature-Sensitive IV Drugs
- Insulin: 2–8°C unopened; max 28°C once opened (28-day limit)
- Oxytocin: store 2–8°C; avoid prolonged room temperature exposure
- Erythropoietin: 2–8°C; 7 days at room temperature
- Immunoglobulins (IVIG): strict 2–8°C; never freeze
- Thrombolytics (tPA): 2–8°C; use within 8h of reconstitution
Storage Requirements
- All IV bags: store per manufacturer — most require <25°C
- Refrigerated items: 2–8°C — never use if found at room temperature for unknown period
- Ambulance/transport: cold-packs mandatory for temperature-sensitive drugs
- Do not leave IV bags in direct sunlight (hospital corridors, windows)
- Photosensitive drugs (e.g., amphotericin, ciprofloxacin, furosemide): wrap in foil
Cold-Chain Monitoring
- Temperature loggers in all medication fridges — review daily
- Fridge temp excursion >8°C or <2°C → quarantine contents; contact pharmacy
- Do not use IV solutions that appear cloudy, discoloured, or precipitated — may be heat-damaged
- Log all cold-chain deviations per hospital policy and GCC regulatory requirements
- Jehovah's Witness patients: May refuse blood and blood products. Ensure advance directive is documented. Discuss blood-sparing alternatives (iron IV, EPO, cell salvage) with medical team proactively.
- Islamic perspective on transfusion: Blood transfusion is generally permissible (halal) in Islam when medically necessary. However, some patients may have personal concerns — always explain clinical necessity respectfully.
- Written informed consent: Required in all GCC countries before blood product transfusion. Ensure interpreter available if language barrier.
- Pre-transfusion prayer: Many Muslim and other religious patients may wish to pray before a procedure. Accommodate this wherever clinically safe to do so.
- Pork-derived products: Heparin is often porcine-derived. Some patients may have concerns. Bovine heparin or fondaparinux may be alternatives — consult with pharmacist and medical team. Document patient's preferences.
- Family involvement: In GCC cultures, family members often play a central decision-making role. Involve family (with patient's consent) in explaining IV therapy, especially for high-alert medications or blood products.
- Gender considerations: Some patients may prefer a nurse of the same gender to perform IV insertions. Accommodate this preference where staffing allows.
- UAE (DHA/DOH): Patient-facing labels must be in Arabic AND English. Internal pharmacy labels: English acceptable.
- Saudi Arabia: SFDA requires Arabic for all patient-facing drug information. English labelling additionally acceptable in international hospitals.
- Qatar/Oman/Bahrain/Kuwait: Arabic + English standard. Many hospitals add Urdu, Hindi, or Filipino translations given large expat nursing workforce and patient population.
- GCC nursing workforce: Many nurses are non-Arabic speakers (Philippines, India, UK, etc.). All IV labels and critical instructions must be in English as a minimum in clinical areas.
- IV medication labels: Must include drug name in both brand and generic form. Avoid abbreviations that could be misread across languages.
- High-alert auxiliary labels: "HIGH ALERT" in English + "دواء عالي الخطورة" in Arabic recommended for all GCC hospitals.